

Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference

September 18, 2017

LAVAL, Quebec, Sept. 18, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, finance and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Cantor Fitzgerald Global Healthcare Conference in New York on Sept. 25, 2017 at 9:45 a.m. EDT.

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at:

<http://ir.valeant.com/events-and-presentations/2017>

.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

.

Forward-looking Statements

This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Investor Contact:

Arthur Shannon

arthur.shannon@valeant.com

Media Contact:

Lainie Keller

lainie.keller@valeant.com

(514) 856-3855

(908) 927-0617

(877) 281-6642 (toll free)



View original content with multimedia:

<http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-cantor-fitzgerald-global-healthcare-conference-300520430.html>

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION